Connect with us

Technology

Senhwa’s CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research

Published

on

TAIPEI and SAN DIEGO, Aug. 12, 2026 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492) today announced a significant research advance involving its investigational drug Pidnarulex (CX-5461). A multinational research team comprising investigators from Poland, Slovakia, France and Senhwa Biosciences in Taiwan found that, under specific cell-based experimental conditions, controlled light activation increased the cancer-cell-killing activity of CX-5461 by up to 96-fold and induced immunogenic cell death (ICD). The findings, published in the peer-reviewed journal Nucleic Acids Research, reveal that CX-5461 may have potential applications in photodynamic therapy and photoimmunotherapy in addition to its established research profile involving G-quadruplex (G4) targeting and DNA-damage-related mechanisms. The study opens a potential new development path for this clinical-stage asset.

Turning Photosensitivity into a Controlled Therapeutic Mechanism
Photosensitivity observed during the clinical development of CX-5461 has generally been viewed as a drug characteristic requiring risk management. In the new study, researchers reframed this property as a potentially controllable and spatially targeted therapeutic mechanism. By applying light of an appropriate wavelength to the tumor area, CX-5461 may be activated at the intended site, increasing local tumor-cell killing while limiting activity in non-illuminated tissue.

This light-switch concept could extend CX-5461 from a systemically administered anticancer agent into a photosensitizer with temporal and spatial control. The approach may warrant further investigation in tumors that are accessible to external light, endoscopy or fiber-optic delivery, including selected skin, oral and esophageal tumors.

Light Activation Triggers Tumor-Cell Killing and Immunogenic Cell Death
The study further showed that light-activated CX-5461 not only directly damaged cancer cells but also induced ICD. When cancer cells die through an immunogenic process, they release or expose danger-associated signals, including cell-surface calreticulin, extracellular ATP and high-mobility group box 1 (HMGB1). These signals can help dendritic cells recognize and take up tumor antigens, potentially initiating a T-cell-mediated antitumor immune response.

The therapeutic objective may therefore extend beyond destroying an illuminated local tumor. By making antigens from dying cancer cells more visible to the immune system, the treatment could provide a biological basis for using localized therapy to stimulate a broader antitumor immune response.

Preclinical Findings Support an In Situ Cancer Vaccine Concept
In preclinical mouse studies, animals whose tumors regressed after treatment with CX-5461 and light exposure showed suppressed tumor growth when subsequently challenged with the same cancer cells. The observation suggests that treatment may establish tumor-specific immune memory and supports further investigation of an in situ cancer vaccine concept. Under this approach, the patient’s own tumor could serve as the source of tumor antigens, allowing an immune response to be initiated at the treatment site without the need to manufacture an external vaccine in advance.

If validated through additional studies, this mechanism could also be explored in combination with immune checkpoint inhibitors targeting PD-1 or PD-L1, with the goal of broadening or prolonging antitumor immune activity. These findings are preclinical and require confirmation in additional animal studies and human clinical trials.

Expanding the Potential Value of an Existing Clinical-Stage Asset
In drug development, a molecule can gain a second life when its existing properties and mechanisms are understood in a new way. CX-5461 has already generated a body of development data across chemistry, manufacturing and controls, toxicology, pharmacology and human clinical safety. The new research reframes photosensitivity as a potentially useful therapeutic mechanism and extends the molecule’s research potential beyond G4 targeting and DNA-damage response into photodynamic therapy, photoimmunotherapy and immune-combination strategies.

Compared with developing an entirely new molecule from the outset, identifying a new mechanism and potential indications for an existing clinical-stage asset may support development continuity and broaden its potential product lifecycle, subject to successful preclinical, regulatory and clinical evaluation.

Next Steps
Senhwa views these findings as an important starting point for repositioning the value of CX-5461. Based on further validation, the Company plans to evaluate suitable tumor types, dosing and illumination conditions, light-delivery technologies and potential combination strategies. Senhwa will also seek multinational academic and industry collaborations to support the clinical translation of this photoimmunotherapy approach.

Additional preclinical and regulatory work will be required before clinical development can proceed. The safety and efficacy of CX-5461 as a photodynamic or photoimmunotherapy treatment have not been established in human clinical trials, and CX-5461 has not been approved for commercial use in these applications.

Please find more details via linkage below:
https://academic.oup.com/nar/article/54/15/gkag777/8758773

About Senhwa Biosciences
Senhwa Biosciences, Inc. is a Taiwan-based biotechnology company developing novel oncology therapeutics for cancers with significant unmet medical needs. Its pipeline includes CX-5461 and CX-4945, which are being evaluated in solid tumors and hematologic malignancies through international clinical and research collaborations. For more information, visit https://www.senhwabio.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/senhwas-cx-5461-opens-a-new-frontier-in-photoimmunotherapy-multinational-study-published-in-nucleic-acids-research-302849454.html

SOURCE SENHWA BIOSCIENCES, INC.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

nubia Neo 5 Max with 7.5-Inch Display Lands as a New PadPhone Category

Published

on

By

SHENZHEN, China, Aug. 12, 2026 /CNW/ — nubia, a highly personalized and lifestyle smartphone brand committed to bringing pro-level gaming to everyone, announced the global rollout of nubia Neo 5 Max, introducing a new PadPhone category that combines the expansive viewing experience of a compact tablet with the portable control of a gaming console. Built around a segment-leading 7.5-inch display, nubia Neo 5 Max brings together pad-level immersion, console-level control, immersive audio-visual feedback and AI-powered gaming assistance in one versatile device for gaming, entertainment and everyday productivity.

“As games become more immersive and young players spend more of their digital lives on mobile devices, the gaming smartphone needs to evolve into a true personal hub,” said Bai Keke, Vice President of ZTE. “At nubia, we are committed to making flagship-level gaming technologies accessible to a broader audience. nubia Neo 5 Max brings the PadPhone concept to life by integrating industry-leading control engineering, a pioneering thermal architecture and flagship-level tuning, where players can play harder, watch bigger and do more wherever they are.”

All-in-One Hub with 7.5-inch Display Leads the New Way for Gaming and Living

nubia Neo 5 Max brings the PadPhone concept with its segment-leading 7.5-inch 1.5K display, delivering 27% more visible area than nubia Neo 5 5G. Featuring an 18.7:9 golden aspect ratio for a more focused gaming experience, the device enlarges enemy outlines by 40% in FPS games. It carries SGS-certified hardware-level eye-care certification for full-scene low blue light and true DC dimming, combined with self-developed eye-caring software functions and smart eye-use reminders, keeping players comfortable every round.

Multiple adaptive modes unlock full potentials of the expansive 7.5-inch display, transforming it into a versatile all-in-one hub. Landscape Mode with protective case stand converts it into a personal mini-TV. E-Ink Mode delivers ink-screen-like visuals for eye-comfort reading, while Controller and Streaming Modes provide responsive, low-latency AAA game casting. For ultimate efficiency, Floating Window and Split-Screen Modes enable seamless multitasking.

Console-Level Control Meets Full-Sensory Immersion

nubia Neo 5 Max features Neo Triggers 5.0 with a 990Hz sampling rate and 4.7ms hardware response latency for fast execution across aiming, firing, moving, and skill activation in a flexible four-finger mode. Designed around C-grip holding style, its 7.5-inch golden control ratio expands the touch area by 27% and widens key spacing by 21% over conventional layouts. Magic Touch 3.0 filters accidental inputs from wet or oily fingers, while a high-precision gyroscope sharpens rotational control, and the 360° Game Antenna ensures stable connectivity.

Dual real symmetrical speakers deliver 300% louder volume accompanied by an anti-obstruction audio design. Powered by Dolby Atmos immersive audio, nubia Neo 5 Max delivers a richer sound experience with incredible depth, clarity, and details that connects users more deeply with their favorite games, movies, music, and more. Z-axis linear motor and RGB Eagle Eye lighting complete the gaming experience by providing haptic feedback for in-game actions and dynamic RGB lighting effects.

30,000mm²+ Cooling System and 7,100mAh Dual-Cell Battery for Marathon Gaming

nubia Neo 5 Max pairs a MediaTek Dimensity 7100 6nm chipset, LPDDR5X memory and UFS 2.2 storage with the NeoTurbo Engine for robust performance, steady frame rates and power efficiency. This model is built with a pioneering 30,000mm²+ cooling system that improves heat-dissipation efficiency by 140% through a dual-layer capillary vapor chamber that expands vapor-liquid circulation pathways and a 3D stamped VC panel for faster heat dissipation. AI Game Space 5.0 provides quick access to gaming tools and intelligent assistance. AI Copilot Demi 2.0 acts as a gaming coach and companion, offering real-time guidance, battle updates and game-related support for players.

A 7,100mAh super dual-cell battery distributes power more efficiently, helping reduce heat and support long-term battery reliability during demanding use. While gaming, Bypass Charging powers the device directly without heating the battery. Even at 5% battery, 5% Extreme Mode keeps players gaming for up to 22.9 minutes.

nubia Neo 5 Max is available first in Southeast Asia as part of its global rollout, coming in Shadow Black, Titanium Gold, and Cyber Silver, offering configurations of 20GB (8GB + 12GB) RAM with 256GB storage or 512GB storage.

MEDIA INQUIRIES:
ZTE Corporation
Communications
Email: ZTE.press.release@zte.com.cn

View original content to download multimedia:https://www.prnewswire.com/news-releases/nubia-neo-5-max-with-7-5-inch-display-lands-as-a-new-padphone-category-302849505.html

SOURCE ZTE Corporation

Continue Reading

Technology

AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD

Published

on

By

New Site Will Support Global Research and Development Capabilities and Advance Scientific Research

HYDERABAD, India, Aug. 12, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced plans to open a new Science and Innovation Center at Genome Valley in Hyderabad. The center will join Amgen’s global Research and Development network, which consists of seven research laboratories, further expanding the company’s research and scientific capabilities.

The new site reflects Amgen’s continued focus on fighting the world’s toughest diseases by harnessing the best of biology and technology. By integrating advanced scientific capabilities with data and digital innovation, the company aims to accelerate the discovery and development of innovative medicines for patients worldwide.

“The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities and complements our strong U.S.-based Research and Development footprint,” said Jay Bradner, M.D., executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. “By connecting these capabilities, we can learn faster and translate those insights into innovative medicines for patients.”

“Hyderabad has built one of the world’s strongest life sciences ecosystems, with deep capabilities in pharmaceuticals and vaccines. The next chapter is about taking that strength into discovery and innovation. Amgen’s decision to establish its Science and Innovation Center in Genome Valley reflects Hyderabad’s growing role as a global hub for high-value research, bringing together scientific talent, technology and industry at scale. Our ambition is to make Hyderabad a place where the next generation of medicines and therapies can be discovered, developed and taken to the world,” said Shri D. Sridhar Babu, Hon’ble Minister for Information Technology, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana.

The center is expected to be operational in 2027, and will bring together scientists and technologists across discovery chemistry, drug metabolism & pharmacokinetics and precision medicine, working closely with Amgen’s research sites around the world. This approach is designed to enhance how medicines are discovered and developed, improving speed, precision, and efficiency.

“This new center reflects Amgen’s commitment to advancing scientific excellence, and India will be an important part of our global R&D network,” said Som Chattopadhyay, senior vice president of Global Business Solutions and national executive at Amgen. “By expanding Amgen’s global research capabilities through its Hyderabad site, we are enabling deep scientific collaboration and look forward to participating in the local innovation ecosystem.”

Genome Valley offers strong scientific expertise and infrastructure, and the new facility will complement Amgen’s existing technology and innovation site in Hyderabad. Together, these sites will enable closer integration of wet-laboratory science with innovative technology, advancing how the company develops medicines.

“Hyderabad’s strong life sciences ecosystem and deep STEM expertise enable us to apply advanced technologies at scale,” said Naveen Gullapalli, managing director, Amgen India. “Our new center at Genome Valley will help integrate biotechnology and digital innovation to serve more patients globally.”

About Amgen 

Amgen discovers, develops, manufactures, and delivers innovative medicines to fight some of the world’s toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity-related conditions.

Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.

 

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/amgen-to-open-new-science–innovation-center-in-genome-valley-hyderabad-302849508.html

Continue Reading

Technology

Indian Music Industry Faces ₹350 Crore Annual Sync Revenue Loss

Published

on

By

Unlicensed Commercial Use Continues to Go Undetected Across Social Platforms

ContentLens Estimates Global Loss at USD 1 Billion Annually

MUMBAI, India, Aug. 12, 2026 /PRNewswire/ — Millions of reels are created every single day across social media platforms in India. The scale of unlicensed commercial use of copyrighted music is staggering. Based on revenue-at-risk assessments conducted with leading labels on the platform, the Indian music industry is estimated to be losing upwards of ₹350 crore annually to unlicensed commercial use of its catalogues. And the labels knew this sync revenue loss was happening.

A year ago, ContentLens gave India’s music labels something they had never had: evidence of who is using their tracks across social media and streaming platforms, complete with timestamps and financial profiling of the infringing entity. The platform’s patent-applied IP Detection Engine goes beyond standard audio matching and manual search methods. It also catches slowed versions, remixes, and unauthorised cover tracks and these manipulations routinely slip through conventional mechanism. Four of India’s leading labels and one international major have been on the platform building their detection capability and recovering their lost sync revenues. Now, ContentLens is closing the loop with a fully managed Enforcement Service i.e. the only platform in the market that takes a music rights violation from identification all the way through to settlement, entirely on the label’s behalf. Two labels have already joined ContentLens for this 360-degree detection-to-settlement enforcement.

One large label’s own internal assessment estimated its annual sync revenue at risk at ₹18 crore from social media infringements alone. Extrapolated across India’s music industry using the revenue market share logic, the total exposure runs upwards of ₹350 crore (approximately USD 40 million) every year.

Globally, the problem is far larger. The recorded music industry is valued at USD 31 billion. Applying conservative market share and licensing-awareness adjustments, ContentLens estimates the global sync revenue loss from unlicensed social media usage at approximately USD 1 billion annually, a largely invisible leak that no label, anywhere, has had the tools to address until now.

In their own words:

“Detection without enforcement is just a filing cabinet. We spent the last year proving our technology works at scale. Across the top 100 songs a label gives us, we detect 80-100 infringing videos every month, 98% of them clearly unlicensed. Today we are closing the loop i.e. from formal notices to negotiations and settlements, entirely managed by ContentLens on the label’s behalf. Zero burden on the label’s team. The music industry finally has a platform that does not just watch. It acts.”

–  Rohan Sahu, Founder & CEO, ContentLens

“Every label head I speak to knows their music is being used without permission. Nobody had a way to prove it, quantify it, or act on it. ContentLens has spent the last year doing exactly that with five leading labels. The data points speak for themselves: ₹350 crore in India, USD 1 billion globally – sync revenue that the industry has been leaving on the table, year after year. Every label can run that math against their own market share and see exactly what they stand to earn.”

–  Hari Nair, Strategic Advisor, ContentLens & Former CEO, Tips Music Limited

Your music is already being used. The only question is whether you are going to get paid for it.

About ContentLens

ContentLens (contentlens.ai) is an AI-powered intellectual property protection platform built for the generative AI era, operating across music IP protection, celebrity likeness and deepfake detection, content provenance (C2PA) and watermarking, and counterfeit detection. Headquartered in Bangalore and backed by the NVIDIA Inception Program and Microsoft for Startups Founders Hub, ContentLens serves music labels, celebrity talent, sports organisations, and enterprise brands seeking to protect their IP at scale.

 

View original content:https://www.prnewswire.com/in/news-releases/indian-music-industry-faces-350-crore-annual-sync-revenue-loss-302849513.html

Continue Reading

Trending